TY - JOUR
T1 - Diarrhea in preschool children and lactobacillus reuteri
T2 - A randomized controlled trial
AU - Gutierrez-Castrellon, Pedro
AU - Lopez-Velazquez, Gabriel
AU - Diaz-Garcia, Luisa
AU - Jimenez-Gutierrez, Carlos
AU - Mancilla-Ramirez, Javier
AU - Estevez-Jimenez, Juliana
AU - Parra, Minerva
PY - 2014/4
Y1 - 2014/4
N2 - OBJECTIVES: To evaluate whether daily administration of Lactobacillus reuteri DSM 17938 reduces the frequency and duration of diarrheal episodes and other health outcomes in day school children in Mexico. METHODS: Healthy children (born at term, aǵed 6-36 months) attending day care centers were enrolled in this randomized, double-blind, placebo-controlled trial. They received L reuteri DSM 17938 (dose 108 colony-forming unit; n = 168) or identical placebo (n = 168) by mouth, daily for 3 months, after which they were followed-up after a further 3 months without supplementation. RESULTS: Data from all children were included in the final analysis. L reuteri DSM 17938 significantly reduced the frequency and duration of episodes of diarrhea and respiratory tract infection at both 3 and 6 months (P < .05). Additionally, the number of doctor visits, antibiotic use, absenteeism from day school and parental absenteeism from work were significantly reduced in the L reuteri group (P < .05). A cost-benefit analysis revealed significant reductions in costs in the L reuteri-treated children. No adverse events related to the study product were reported. CONCLUSIONS: In healthy children attending day care centers, daily administration of L reuteri DSM 17938 had a significant effect in reducing episodes and duration of diarrhea and respiratory tract infection, with consequent cost savings for the community.
AB - OBJECTIVES: To evaluate whether daily administration of Lactobacillus reuteri DSM 17938 reduces the frequency and duration of diarrheal episodes and other health outcomes in day school children in Mexico. METHODS: Healthy children (born at term, aǵed 6-36 months) attending day care centers were enrolled in this randomized, double-blind, placebo-controlled trial. They received L reuteri DSM 17938 (dose 108 colony-forming unit; n = 168) or identical placebo (n = 168) by mouth, daily for 3 months, after which they were followed-up after a further 3 months without supplementation. RESULTS: Data from all children were included in the final analysis. L reuteri DSM 17938 significantly reduced the frequency and duration of episodes of diarrhea and respiratory tract infection at both 3 and 6 months (P < .05). Additionally, the number of doctor visits, antibiotic use, absenteeism from day school and parental absenteeism from work were significantly reduced in the L reuteri group (P < .05). A cost-benefit analysis revealed significant reductions in costs in the L reuteri-treated children. No adverse events related to the study product were reported. CONCLUSIONS: In healthy children attending day care centers, daily administration of L reuteri DSM 17938 had a significant effect in reducing episodes and duration of diarrhea and respiratory tract infection, with consequent cost savings for the community.
KW - Children
KW - Diarrhea
KW - Lactobacillus reuteri DSM 17938
UR - http://www.scopus.com/inward/record.url?scp=84898735116&partnerID=8YFLogxK
U2 - 10.1542/peds.2013-0652
DO - 10.1542/peds.2013-0652
M3 - Artículo
C2 - 24639271
SN - 0031-4005
VL - 133
SP - e904-e909
JO - Pediatrics
JF - Pediatrics
IS - 4
ER -